Evidence map›Paper›PMID 26510189›Full record

ArticlePloS one2015

Enzymatic Characterization of Recombinant Food Vacuole Plasmepsin 4 from the Rodent Malaria Parasite Plasmodium berghei.

Peng Liu, Arthur H Robbins, Melissa R Marzahn, Scott H McClung, Charles A Yowell, Stanley M Stevens, John B Dame, Ben M Dunn

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Peng LiuDepartment of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Gainesville, Florida, United States of America.
Arthur H RobbinsDepartment of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Gainesville, Florida, United States of America.
Melissa R MarzahnDepartment of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Gainesville, Florida, United States of America.
Scott H McClungProtein Core, Interdisciplinary Center for Biotechnology Research, University of Florida, College of Medicine, Gainesville, Florida, United States of America.
Charles A YowellDepartment of Infectious Diseases and Pathology, University of Florida, College of Veterinary Medicine, Gainesville, Florida, United States of America.
Stanley M StevensProtein Core, Interdisciplinary Center for Biotechnology Research, University of Florida, College of Medicine, Gainesville, Florida, United States of America.
John B DameDepartment of Infectious Diseases and Pathology, University of Florida, College of Veterinary Medicine, Gainesville, Florida, United States of America.
Ben M DunnDepartment of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Gainesville, Florida, United States of America.
Florida College · USUniversity of Florida · US

Funding

PLASMEPSINS AS ANTIMALARIAL DRUG TARGETSR01AI039211 · NIAID · UNIVERSITY OF FLORIDA · PI DAME, JOHN B. · 1996 to 1999
–
NIAID NIH HHS AI39211
6 · The paper itself

Abstract

The rodent malaria parasite Plasmodium berghei is a practical model organism for experimental studies of human malaria. Plasmepsins are a class of aspartic proteinase isoforms that exert multiple pathological effects in malaria parasites. Plasmepsins residing in the food vacuole (FV) of the parasite hydrolyze hemoglobin in red blood cells. In this study, we cloned PbPM4, the FV plasmepsin gene of P. berghei that encoded an N-terminally truncated pro-segment and the mature enzyme from genomic DNA. We over-expressed this PbPM4 zymogen as inclusion bodies (IB) in Escherichia coli, and purified the protein following in vitro IB refolding. Auto-maturation of the PbPM4 zymogen to mature enzyme was carried out at pH 4.5, 5.0, and 5.5. Interestingly, we found that the PbPM4 zymogen exhibited catalytic activity regardless of the presence of the pro-segment. We determined the optimal catalytic conditions for PbPM4 and studied enzyme kinetics on substrates and inhibitors of aspartic proteinases. Using combinatorial chemistry-based peptide libraries, we studied the active site preferences of PbPM4 at subsites S1, S2, S3, S1', S2' and S3'. Based on these results, we designed and synthesized a selective peptidomimetic compound and tested its inhibition of PbPM4, seven FV plasmepsins from human malaria parasites, and human cathepsin D (hcatD). We showed that this compound exhibited a >10-fold selectivity to PbPM4 and human malaria parasite plasmepsin 4 orthologs versus hcatD. Data from this study furthesr our understanding of enzymatic characteristics of the plasmepsin family and provides leads for anti-malarial drug design.

Indexed as

Amino Acid SubstitutionAnimalsAspartic Acid EndopeptidasesCatalysisCatalytic DomainEnzyme ActivationGene ExpressionKineticsPlasmodium bergheiProtein RefoldingProtozoan ProteinsRecombinant ProteinsAspartic Acid EndopeptidasesplasmepsinProtozoan ProteinsRecombinant Proteins

Identifiers

PMID26510189
PMCPMC4624963
OpenAlexW2252923209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.